BDA-366(b)
CAS No. 1821496-27-8
BDA-366(b) ( BDA-366; BDA 366; BDA366 )
产品货号. M17388 CAS No. 1821496-27-8
BDA-366 specifically targets the BH4 domain of Bcl2 BDA-366 and suppresses human myeloma growth. BDA-366 induces robust apoptosis in MM cell lines and primary MM cells by inducing BCL2 conformational change.
纯度: 98%
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
规格 | 价格/人民币 | 库存 | 数量 |
2MG | ¥547 | 有现货 |
|
5MG | ¥979 | 有现货 |
|
10MG | ¥1570 | 有现货 |
|
25MG | ¥3246 | 有现货 |
|
50MG | ¥5221 | 有现货 |
|
100MG | 获取报价 | 有现货 |
|
200MG | 获取报价 | 有现货 |
|
500MG | 获取报价 | 有现货 |
|
1G | 获取报价 | 有现货 |
|
生物学信息
-
产品名称BDA-366(b)
-
注意事项本公司产品仅用于科研实验,不得用于人体或动物的临床与诊断
-
产品简述BDA-366 specifically targets the BH4 domain of Bcl2 BDA-366 and suppresses human myeloma growth. BDA-366 induces robust apoptosis in MM cell lines and primary MM cells by inducing BCL2 conformational change.
-
产品描述BDA-366 is a BCL2-BH4 antagonist. BDA-366 suppresses human myeloma growth. BDA-366 induces robust apoptosis in MM cell lines and primary MM cells by inducing BCL2 conformational change. Delivery of BDA-366 substantially suppressed the growth of human MM xenografts in NOD-scid/IL2Rγnull mice, without significant cytotoxic effects on normal hematopoietic cells or body weight. Thus, BDA-366 functions as a novel BH4-based BCL2 inhibitor and offers an entirely new tool for MM therapy.
-
同义词BDA-366; BDA 366; BDA366
-
通路Others
-
靶点Other Targets
-
受体Bcl-2-BH4
-
研究领域——
-
适应症——
化学信息
-
CAS Number1821496-27-8
-
分子量423.26
-
分子式C24H29N3O4
-
纯度98%
-
溶解度——
-
SMILESCCN(CC)C[C@@H](O)CNc1ccc(NC[C@H]2CO2)c2C(=O)c3ccccc3C(=O)c12
-
化学全称1-(((S)-3-(diethylamino)-2-hydroxypropyl)amino)-4-((((S)-oxiran-2-yl)methyl)amino)anthracene-9,10-dione
运输与储存
-
储存条件(-20℃)
-
运输条件With Ice Pack
-
稳定性≥ 2 years
参考文献
产品手册
关联产品
-
Quercetin 3,7-digluc...
Quercetin 3,7-diglucoside exhibits antioxidant activity.
-
N-Acetyl-O-phosphono...
Phosphopeptide; binds to the src SH2 domain.
-
PH-002
PH-002 is an inhibitor of apolipoprotein (apo) E4 intramolecular domain interaction in neuronal cells. It also could rescue impairments of mitochondrial motility and neurite outgrowth.